Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: An analysis from the lymphoma working party of the European group for blood and marrow transplantation

被引:226
作者
Sureda, Anna
Robinson, Stephen
Canals, Carmen
Carella, Angela M.
Boogaerts, Marc A.
Caballero, Dolores
Hunter, Ann E.
Kanz, Lothar
Slavin, Shimon
Cornelisson, Jan J.
Gramatzki, Martin
Niederwieser, Dietger
Russell, Nigel H.
Schmitz, Norbert
机构
[1] Clinical Hematology Division, Hospital de la Santa Creu I Sant Pau, 08025 Barcelona, Antoni Maria i Claret
关键词
D O I
10.1200/JCO.2007.13.2415
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose To compare the clinical outcome in terms of nonrelapse mortality (NRM), relapse rate (RR), overall survival ( OS), and progression-free survival (PFS) in patients with relapsed Hodgkin's lymphoma (HL) treated with reduced-intensity conditioning (RIC) or myeloablative conditioning followed by allogeneic stem-cell transplantation (alloSCT). Patients and Methods A total of 168 patients with HL undergoing a first alloSCT ( RIC, n = 89; myeloablative conditioning, n = 79) between January 1997 and December 2001 and registered in the European Group for Blood and Marrow Transplantation database were analyzed. Results NRM was significantly decreased in the RIC group ( hazard ratio [HR], 2.85; 95% CI, 1.62 to 5.02; P =.001). OS was better in the RIC group ( HR, 2.05; 95% CI, 1.27 to 3.29; P =.04) and there was a trend for better PFS in the RIC group ( HR, 1.53; 95% CI, 0.97 to 2.40; P =.07). RR was higher in the RIC group in univariate but not in multivariate analysis. The development of chronic graft-versus-host disease (GVHD) significantly decreased the incidence of relapse, which translated into a trend for a better PFS. Conclusion The lower incidence of NRM in the RIC group is encouraging, particularly because these patients experienced adverse pretransplantation characteristics more frequently. This analysis also indicates the existence of a graft-versus-HL effect correlated to the development of GVHD. Additional efforts to reduce the high RR seen in both groups of patients will be necessary to improve the modest PFS (31% v 27%) and OS (59% v 36%) for patients prepared with RIC or myeloablative conditioning.
引用
收藏
页码:455 / 462
页数:8
相关论文
共 27 条
[11]   Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy [J].
Giralt, S ;
Estey, E ;
Albitar, M ;
vanBesien, K ;
Rondon, G ;
Anderlini, P ;
OBrien, S ;
Khouri, I ;
Gajewski, J ;
Mehra, R ;
Claxton, D ;
Andersson, B ;
Beran, M ;
Przepiorka, D ;
Koller, C ;
Kornblau, S ;
Korbling, M ;
Keating, M ;
Kantarjian, H ;
Champlin, R .
BLOOD, 1997, 89 (12) :4531-4536
[12]  
JONES RJ, 1991, BLOOD, V77, P649
[13]   Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group [J].
Josting, A ;
Rueffer, U ;
Franklin, J ;
Sieber, M ;
Diehl, V ;
Engert, A .
BLOOD, 2000, 96 (04) :1280-1286
[14]   Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part I: Unadjusted analysis [J].
Klein, JP ;
Rizzo, JD ;
Zhang, MJ ;
Keiding, N .
BONE MARROW TRANSPLANTATION, 2001, 28 (10) :909-915
[15]   Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part 2: Regression modeling [J].
Klein, JP ;
Rizzo, JD ;
Zhang, MJ ;
Keiding, N .
BONE MARROW TRANSPLANTATION, 2001, 28 (11) :1001-1011
[16]   DONOR LEUKOCYTE TRANSFUSIONS FOR TREATMENT OF RECURRENT CHRONIC MYELOGENOUS LEUKEMIA IN MARROW TRANSPLANT PATIENTS [J].
KOLB, HJ ;
MITTERMULLER, J ;
CLEMM, C ;
HOLLER, E ;
LEDDEROSE, G ;
BREHM, G ;
HEIM, M ;
WILMANNS, W .
BLOOD, 1990, 76 (12) :2462-2465
[17]   Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe [J].
Ljungman, P ;
Urbano-Ispizua, A ;
Cavazzana-Calvo, M ;
Demirer, T ;
Dini, G ;
Einsele, H ;
Gratwohl, A ;
Madrigal, A ;
Niederwieser, D ;
Passweg, J ;
Rocha, V ;
Saccardi, R ;
Schouten, H ;
Schmitz, N ;
Socie, G ;
Sureda, A ;
Apperley, J .
BONE MARROW TRANSPLANTATION, 2006, 37 (05) :439-449
[18]   Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease [J].
Milpied, N ;
Fielding, AK ;
Pearce, RM ;
Ernst, P ;
Goldstone, AH .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (04) :1291-1296
[19]   Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation [J].
Peggs, KS ;
Hunter, A ;
Chopra, R ;
Parker, A ;
Mahendra, P ;
Milligan, D ;
Craddock, C ;
Pettengell, R ;
Dogan, A ;
Thomson, KJ ;
Morris, EC ;
Hale, G ;
Waldmann, H ;
Goldstone, AH ;
Linch, DC ;
Mackinnon, S .
LANCET, 2005, 365 (9475) :1934-1941
[20]   An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation [J].
Peniket, AJ ;
de Elvira, MCR ;
Taghipour, G ;
Cordonnier, C ;
Gluckman, E ;
de Witte, T ;
Santini, G ;
Blaise, D ;
Greinix, H ;
Ferrant, A ;
Cornelissen, J ;
Schmitz, N ;
Goldstone, AH .
BONE MARROW TRANSPLANTATION, 2003, 31 (08) :667-678